Exicure to Present AST-008 Updates at 2020 AACR Virtual Annual Meeting
May 05 2020 - 7:00AM
Business Wire
Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, will present at the American Association of Cancer
Research (AACR) Virtual Annual Meeting II, occurring June 22 – 24,
2020.
The AACR poster titled “Phase 1b/2 Study of an Intratumoral TLR9
Agonist Spherical Nucleic Acid (AST-008) and Pembrolizumab:
Evidence of Immune Activation” will present updated pharmacodynamic
and safety data of AST-008 alone and in combination with
pembrolizumab from Exicure’s ongoing Phase 1b/2 study
(ClinicalTrials.gov identifier: NCT03684785).
This poster will be presented during the AACR Virtual Meeting II
in the session Late-Breaking Research: Clinical Research 1 /
Endocrinology under abstract number LB-140. The abstract will be
available for viewing on May 15th and the poster will be available
for viewing on June 22nd.
About AST-008
AST-008 is an SNA consisting of toll-like receptor 9 agonists
designed for immuno-oncology applications. As of January 31, 2020,
we have dosed 17 patients in the Phase 1b stage of the clinical
trial. We have observed no treatment related serious adverse
events, nor have we observed any dose-limiting toxicity among the
treated subjects. The most common reported adverse event was
injection site reactions. In December 2019, we received preliminary
results from the Phase 1b/2 stage of the clinical trial showing
potential signs of anti-tumor activity in patients with Merkel cell
carcinoma. In the second quarter of 2020, we plan to initiate a
Phase 2 dose expansion for intratumoral AST-008 in combination with
approved checkpoint inhibitors to treat two cohorts of patients
with advanced or metastatic Merkel cell carcinoma or cutaneous
squamous cell carcinoma. Each cohort is expected to enroll up to 29
patients who have failed anti-PD-1/PD-L1, or programmed cell death
protein 1/programmed death-ligand 1, therapy. We expect to open a
total of up to 15 sites in the United States.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for neurology, immuno-oncology,
inflammatory diseases and genetic disorders based on our
proprietary Spherical Nucleic Acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN, an
SNA–based therapeutic candidate for the treatment of Friedreich’s
ataxia (FA). Exicure's drug candidate AST-008 is currently in a
Phase 1b/2 clinical trial in patients with advanced solid tumors.
Exicure is based outside of Chicago, IL and also has an office in
Cambridge, MA. For more information, visit Exicure’s website at
www.exicuretx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200505005186/en/
Media Contact Karen Sharma MacDougall 781-235-3060
ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024